participant.ui.study.eligibility-status-cta.not-recruiting
common.study.topics.clinical

Treatment of Prostate Cancer

common.study.values.description

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to assess the safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Biological - nivolumab

Specified dose on specified days

Drug - docetaxel

Specified dose on specified days

Drug - enzalutamide

Specified dose on specified days

Drug - rucaparib

Specified dose on specified days

Drug - prednisone

Specified dose on specified days

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

common.study.values.clinical-trial-id

NCT03338790

participant.views.study.view.id

nel3Jd